China eyes Southeast Asia to build legitimacy for its COVID-19 vaccine despite unclear efficacy data
China has found major buyers for its COVID-19 vaccines in Southeast Asia, even after studies of its Sinovac vaccine have reported wildly divergent efficacy results. The growing acceptance of Beijing’s vaccine without globally-recognized clinical trial results may end up undermining China’s image as a credible vaccine supplier.